01Mar/18

Phase 2 Data for Roche’s Lymphoma ADC Doesn’t Disappoint

March 1, 2018Antibody-drug Conjugates Research, Newsantibody drug conjugates, fdabioadc

With breakthrough designation from the FDA and priority medicine status in the EU, expectations for Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab vedotin are running pretty high. Phase 2 data presented atRead More…

08Feb/18

AMID Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes Massachusetts Facility

February 8, 2018Antibody-drug Conjugates Research, Newsantibody drug conjugate pepline, antibody drug conjugatesbioadc

A leader in the expanding field of antibody-drug conjugates or ADCs for the treatment of cancer, Immunogen last week highlighted some of the company’s the operating results for 2017. Immunogen is a clinical-stage biotechnologyRead More…

Home
Antibody-drug Conjugates Research
Antibody-drug Conjugates Manufacturing
News

DrugLnk™ Custom Synthesis

Antibody Design and Conjugation

Customized ADCs

ADC Analysis

Phase 2 Data for Roche’s Lymphoma ADC Doesn’t Disappoint

AMID Significant Progress, Robust Growth and Advancing Pipeline — Immunogen Closes Massachusetts Facility